O ver the 5 decades that bioprosthetic valves (BPVs) have been commonly implanted, the frequency of superimposed thrombosis has been thought to be negligible (1) . Thus, early echocardiographic follow-up of patients with BPVs has been sparse, and chronic anticoagulation was mostly avoided. After the baseline post-operative study, current guidelines state that "patients with bioprosthetic valves may be considered for annual echocardiography after the first 5 years in the absence of a change in clinical status," prior to which routine echo is "not indicated" (2) . When increased gradients or bioprosthetic leaflet dysfunction is discovered, the treatment recommended is frequently reoperation. However, computed tomography cannot measure valve gradients, and its expense and radiation exposure limit its use for serial observations of BPV.
In this issue of the

VALUE OF SERIAL DOPPLER-DERIVED GRADIENTS
A change in gradient >50% above baseline within 5 years was 1 of the variables most predictive of BPVT. Clinic Foundation, Cleveland, Ohio. Dr. Stewart has reported that he has no relationships relevant to the contents of this paper to disclose. 
THERAPEUTIC WARFARIN TREATMENT
Once thrombosis is diagnosed by higher-thanexpected gradients with thick, restricted leaflets, the current paper recommends treatment with warfarin, with close echocardiographic follow-up. Concerned that our inattention to the potential for thrombi to develop on BPV may "blind" our echocardiographic diagnosis of the thrombotic process, Pislaru et al. (8) proposed an algorithm for managing BPVT that has been adapted in Figure 1 to include the active surveillance strategies and management options mentioned in this editorial.
Assuming that the patient groups manifest the important differences between thrombosis and degenerative changes of BPV, this paper by Egbe et al. 
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